| 0.71 0.017 (2.45%) | 06-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
HEXO Corp. operates as a Canadian cannabis firm, utilizing its subsidiaries to cultivate, market, and distribute various cannabis products throughout the country. Its flagship HEXO brand caters to both the adult-use recreational and medicinal cannabis markets. Beyond its core offerings, the company provides a diverse range of cannabis-infused beverages, including popular labels such as Little Victory, House of Terpenes, Mollo, Veryvell, and XMG. Additionally, HEXO markets other cannabis products under distinct brands like UP Cannabis, Original Stash, and Up. The company has forged a significant strategic alliance with Tilray Brands, Inc. Founded in 2013, HEXO Corp. was originally known as The Hydropothecary Corporation before adopting its current name in August 2018. Its principal office is situated in Gatineau, Canada.
Mon, 07 Jul 2025
Dionne c. HEXO Corp.: When Proof is in the Pudding - McCarthy Tétrault
Tue, 10 Jun 2025
Québec Court of Appeal dismisses HEXO securities class action - Norton Rose Fulbright
Wed, 26 Mar 2025
Tilray Successfully Prevails with Dismissal of HEXO Shareholder Lawsuit - Yahoo Finance
Fri, 23 Jun 2023
Marijuana company Tilray closes Hexo acquisition, eyes cost savings - MJBizDaily
Thu, 15 Jun 2023
Cannabis producer Hexo’s accumulated losses surpass CA$2 billion - MJBizDaily
Mon, 10 Apr 2023
Cannabis producer Tilray to buy Hexo for $56 mln - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|